ORIC vs. NRIX, WVE, ZYME, MLYS, CALT, STOK, GHRS, COGT, OLMA, and SIGA
Should you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Nurix Therapeutics (NRIX), Wave Life Sciences (WVE), Zymeworks (ZYME), Mineralys Therapeutics (MLYS), Calliditas Therapeutics AB (publ) (CALT), Stoke Therapeutics (STOK), GH Research (GHRS), Cogent Biosciences (COGT), Olema Pharmaceuticals (OLMA), and SIGA Technologies (SIGA). These companies are all part of the "pharmaceutical preparations" industry.
Nurix Therapeutics (NASDAQ:NRIX) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.
Nurix Therapeutics received 1 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. Likewise, 70.15% of users gave Nurix Therapeutics an outperform vote while only 65.71% of users gave ORIC Pharmaceuticals an outperform vote.
In the previous week, ORIC Pharmaceuticals had 10 more articles in the media than Nurix Therapeutics. MarketBeat recorded 16 mentions for ORIC Pharmaceuticals and 6 mentions for Nurix Therapeutics. ORIC Pharmaceuticals' average media sentiment score of 0.71 beat Nurix Therapeutics' score of 0.64 indicating that Nurix Therapeutics is being referred to more favorably in the media.
Nurix Therapeutics currently has a consensus price target of $21.33, suggesting a potential upside of 52.60%. ORIC Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 108.33%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ORIC Pharmaceuticals is more favorable than Nurix Therapeutics.
Nurix Therapeutics has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.
95.1% of ORIC Pharmaceuticals shares are held by institutional investors. 9.8% of Nurix Therapeutics shares are held by insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ORIC Pharmaceuticals has a net margin of 0.00% compared to ORIC Pharmaceuticals' net margin of -178.93%. Nurix Therapeutics' return on equity of -42.71% beat ORIC Pharmaceuticals' return on equity.
ORIC Pharmaceuticals has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
ORIC Pharmaceuticals beats Nurix Therapeutics on 11 of the 17 factors compared between the two stocks.
Get ORIC Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ORIC Pharmaceuticals Competitors List
Related Companies and Tools
